Recruiting
Phase 3

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Sponsor:

Cerevance

Code:

NCT06553027

Conditions

Parkinson Disease

Eligibility Criteria

Sex: All

Age: 30+

Healthy Volunteers: Not accepted

Interventions

CVN424 75 mg

CVN424 150 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information